Hyperion Therapeutics Inc, Clal, Weizmann Institute of Science deal

Hyperion and Clal settled an ongoing dispute related to the development of DiaPep277 and partnered to complete the Phase III DIA-AID 2 trial

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE